在体内外实验中观察我国首创合成的新钙拮抗剂双苯氟嗪(Dip)对血小板聚集和实验性血栓形成的作用。Dip iv 1—2mg·kg~(-1)和1—100μmol·L~(-1)体外温育可剂量或浓度依赖性地抑制ADP和AA诱发的家兔血小板聚集。Dip iv 2.5—10 mg·kg~(-1)和ip 50—100 mg·kg~(-1)可抑制大鼠体内血栓形成;Dip iv 10mg·kg~(-1)和200μmol·L~(-1)体外给药可抑制体外血栓形成。提示,减轻紊乱的血小板与血管壁反应是其抗血栓作用的主要因素,Dip的作用强于Cin。 In vitro and in vivo experiments observed in our first synthesis of new calcium antagonist dipyridazine (Dip) on platelet aggregation and experimental thrombosis role. In vitro incubation with Dip iv 1-2 mg · kg -1 and 1-100 μmol·L -1 could inhibit platelet aggregation induced by ADP and AA in a dose- or concentration-dependent manner in rabbits. Dip iv 2.5-10 mg · kg -1 and ip 50-100 mg · kg -1 could inhibit thrombus formation in vivo. Dip iv 10 mg · kg -1 and 200 μmol·L -1 -1) In vitro administration suppresses in vitro thrombosis. Tip, to reduce the disturbance of platelet and vascular wall reaction is the main factor in its anti-thrombosis, Dip stronger than Cin.